RESUMEN
Phenylbutazone (PBZ) is a widely used nonsteroidal anti-inflammatory drug for horses. However, because of its gastrointestinal side effects, its administration requires careful attention in veterinary practice. Malondialdehyde (MDA) is a serum biomarker associated with increased damage to the equine gastrointestinal system. This study investigated the hematological effects and alterations in the gastrointestinal tract and assessed serum MDA concentrations following repeated oral PBZ administration at clinical doses. Fourteen horses were randomly divided into control and treatment groups. All horses in the treatment group were administered 4.4 milligrams per kilogram of body weight of PBZ syrup orally twice a day for 7 days, whereas the control group received syrup as a placebo. The development of gastrointestinal side effects was investigated using gastroscopy, abdominal ultrasound, and fecal pH; serum MDA concentrations were assessed using a commercially available enzyme-linked immunosorbent assay kit. Data were compared between PBZ-treated and control horses before and after the treatment period. The treatment group exhibited decreased albumin and total protein concentrations. Moreover, this group exhibited a higher thickness of the right dorsal colon wall (p = 0.03) and had higher scores for squamous gastric ulcers (p = 0.01). Fecal pH was lower in the treatment group than in the control group after PBZ administration (p < 0.01). Although MDA concentrations were higher in the treatment group after PBZ administration, they did not differ significantly from those of the control group. This study highlighted the changes in hematological and gastrointestinal lesions resulting from PBZ administration in horses at clinical doses, even without clinical signs. However, MDA may not be an optimal biomarker for the early detection of gastrointestinal damage due to PBZ treatment in horses.
Asunto(s)
Antiinflamatorios no Esteroideos , Enfermedades de los Caballos , Malondialdehído , Fenilbutazona , Animales , Caballos , Fenilbutazona/administración & dosificación , Fenilbutazona/efectos adversos , Malondialdehído/sangre , Enfermedades de los Caballos/inducido químicamente , Enfermedades de los Caballos/tratamiento farmacológico , Enfermedades de los Caballos/sangre , Administración Oral , Masculino , Antiinflamatorios no Esteroideos/administración & dosificación , Femenino , Enfermedades Gastrointestinales/veterinaria , Enfermedades Gastrointestinales/inducido químicamente , Enfermedades Gastrointestinales/sangre , Tracto Gastrointestinal/efectos de los fármacosRESUMEN
OBJECTIVE: To determine the effects of a single dose of the NSAIDs phenylbutazone, firocoxib, flunixin meglumine, and ketoprofen on concentrations of growth factors and cytokines in autologous protein solution (APS) and platelet-rich plasma (PRP). ANIMALS: 6 adult university-owned horses. METHODS: For the first phase, 6 horses were randomized to receive ketoprofen (1,000 mg) or flunixin meglumine (500 mg) IV. Blood was obtained and processed for APS (Pro-Stride) and PRP (Restigen) before and 6 hours after administration of NSAIDs. Horses underwent a 2-week washout period, after which the protocol was repeated using a crossover design. For the second phase, following at least a 2-week washout period, the study protocol was repeated with phenylbutazone (1 g) or firocoxib (57 mg) administered orally. Plasma was collected 6 hours after administration for evaluation of drug concentrations, and APS and PRP were analyzed for concentrations of drug, platelets, leukocytes, and several growth factors and cytokines (PDGF, fibroblast growth factor, TGF-ß1, IL-1ß, IL-10, IL-6, IL-8, and tumor necrosis factor-α) before and 6 hours after administration of NSAIDs using immunoassays. RESULTS: There were no significant differences in concentrations of cytokines or growth factors before or after administration of any NSAID. There were significant differences in concentrations of leukocytes and platelets based on both product and time. NSAID concentrations in plasma were not significantly different from concentrations in APS and PRP. CLINICAL RELEVANCE: These results help guide clinicians on the appropriate use of these NSAIDs in conjunction with the processing of APS and PRP, which is unlikely to significantly alter the final product after single-dose administration.
Asunto(s)
Antiinflamatorios no Esteroideos , Citocinas , Caballos , Plasma Rico en Plaquetas , Animales , 4-Butirolactona/administración & dosificación , 4-Butirolactona/efectos adversos , 4-Butirolactona/análogos & derivados , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/efectos adversos , Citocinas/sangre , Citocinas/metabolismo , Caballos/sangre , Caballos/metabolismo , Cetoprofeno/administración & dosificación , Cetoprofeno/efectos adversos , Fenilbutazona/administración & dosificación , Fenilbutazona/efectos adversos , Plasma Rico en Plaquetas/metabolismo , Sulfonas/administración & dosificación , Sulfonas/efectos adversos , Distribución AleatoriaRESUMEN
Phenylbutazone (PBZ) is a potent mon-steroidal anti-inflammatory drug used commonly in performance horses. The objectives of the current study were to describe blood and urine concentrations and the pharmacokinetics of PBZ and its metabolites following intravenous (IV) and oral administration and to describe the duration of pharmacodynamic effect. To that end, 17 horses received an IV administration and 18 horses an oral administration of 2 g of PBZ. Blood and urine samples were collected prior to and for up to 96 hours post drug administration. Whole blood samples were collected at various time points and challenged with lipopolysaccharide or calcium ionophore to induce ex vivo synthesis of eicosanoids. Concentrations of PBZ and eicosanoids were measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS) and non-compartmental pharmacokinetic analysis performed on concentration data from IV and oral administration. Serum concentrations of PBZ and its metabolites were below the limit of quantitation at 96 hours post administration. The volume of distribution at steady state, systemic clearance, and terminal half-life was 0.194 ± 0.019 L/kg, 23.9 ± 4.48 mL/h/kg, and 10.9 ± 5.32 hours, respectively. The terminal half-life following oral administration was 13.4 ± 3.01 (paste) and 15.1 ± 3.96 hours (tablets). Stimulation of PBZ treated whole blood with lipopolysaccharide and calcium ionophore resulted in an inhibition of TXB2 , PGE2 , LTB4 and 15-HETE production for a prolonged period of time post drug administration. The results of this study suggest that PBZ has a prolonged anti-inflammatory following IV or oral administration of 2 g to horses.
Asunto(s)
Antiinflamatorios no Esteroideos/administración & dosificación , Enfermedades de los Caballos/prevención & control , Caballos , Inflamación/veterinaria , Fenilbutazona/administración & dosificación , Administración Intravenosa , Administración Oral , Animales , Antiinflamatorios no Esteroideos/sangre , Antiinflamatorios no Esteroideos/orina , Biomarcadores/sangre , Monitoreo de Drogas , Eicosanoides/sangre , Enfermedades de los Caballos/sangre , Enfermedades de los Caballos/diagnóstico , Caballos/sangre , Caballos/orina , Inflamación/sangre , Inflamación/diagnóstico , Inflamación/prevención & control , Fenilbutazona/sangre , Fenilbutazona/orinaRESUMEN
Non-steroidal anti-inflammatory drugs (NSAIDs) are routinely used in both veterinary and human medicine. Gastrointestinal injury is a frequent adverse event associated with NSAID use and evidence suggests that NSAIDs induce gastrointestinal microbial imbalance (i.e., dysbiosis) in both animals and people. It is unknown, however, whether cyclooxygenase (COX)-2-selective NSAIDs induce dysbiosis, or if this phenomenon occurs in horses administered any class of NSAIDs. Therefore, our objectives were to determine whether the composition and diversity of the fecal microbiota of adult horses were altered by NSAID use, and whether these effects differed between non-selective and COX-2-selective NSAIDs. Twenty-five adult horses were randomly assigned to 1 of 3 groups: control (n = 5); phenylbutazone (n = 10); or, firocoxib (n = 10). Treatments were administered for 10 days. Fecal samples were collected every 5 days for 25 days. DNA was extracted from feces and the 16S rRNA gene amplified and sequenced to determine the composition of the microbiota and the inferred metagenome. While the fecal microbiota profile of the control group remained stable over time, the phenylbutazone and firocoxib groups had decreased diversity, and alteration of their microbiota profiles was most pronounced at day 10. Similarly, there were clear alterations of the inferred metagenome at day 10 compared to all other days, indicating that use of both non-selective and selective COX inhibitors resulted in temporary alterations of the fecal microbiota and inferred metagenome. Dysbiosis associated with NSAID administration is clinically relevant because dysbiosis has been associated with several important diseases of horses including abdominal pain (colic), colitis, enteric infections, and laminitis.
Asunto(s)
Antiinflamatorios no Esteroideos/administración & dosificación , Inhibidores de la Ciclooxigenasa 2/administración & dosificación , Microbiota/efectos de los fármacos , ARN Ribosómico 16S/genética , 4-Butirolactona/administración & dosificación , 4-Butirolactona/efectos adversos , 4-Butirolactona/análogos & derivados , Adulto , Animales , Antiinflamatorios no Esteroideos/efectos adversos , Ciclooxigenasa 2/genética , Inhibidores de la Ciclooxigenasa 2/efectos adversos , Heces/microbiología , Caballos/microbiología , Humanos , Metagenoma/efectos de los fármacos , Fenilbutazona/administración & dosificación , Fenilbutazona/efectos adversos , Sulfonas/administración & dosificación , Sulfonas/efectos adversosRESUMEN
The efficacy of oral phenylbutazone [PBZ; 4.4 mg/kg body weight (BW), q12h], a non-selective non-steroidal anti-inflammatory drug (NSAID), and oral meloxicam (MXM; 0.6 mg/kg BW, q24h), a COX-2 selective NSAID, were evaluated in 2 experimental pain models in horses: the adjustable heart bar shoe (HBS) model, primarily representative of mechanical pain, and the lipopolysaccharide-induced synovitis (SYN) model, primarily representative of inflammatory pain. In the HBS model, PBZ reduced multiple indicators of pain compared with the placebo and MXM. Meloxicam did not reduce indicators of pain relative to the placebo. In the SYN model, MXM and PBZ reduced increases in carpal skin temperature compared to the placebo. Meloxicam reduced lameness scores and lameness-induced changes in head movement compared to the placebo and PBZ. Phenylbutazone reduced lameness-induced change in head movement compared to the placebo. Overall, PBZ was more effective than MXM at reducing pain in the HBS model, while MXM was more effective at reducing pain in the SYN model at the oral doses used.
Efficacité comparative du méloxicam oral et de la phénylbutazone dans deux modèles de douleur expérimentaux chez le cheval. L'efficacité de la phénylbutazone orale [PBZ; 4,4 mg/kg poids corporel (PC), q12h], d'un anti-inflammatoire non stéroïdien (AINS) non sélectif, et du méloxicam oral (MXM; 0,6 mg/kg PC, q24h), d'un AINS COX-2 sélectif, ont été évalués dans deux modèles de douleur expérimentaux chez des chevaux : le modèle du fer en cÅur ajustable (HBS), qui représente surtout la douleur mécanique, et le modèle de la synovite induite par le lipopolysaccharide (SYN), qui représente principalement la douleur inflammatoire. Dans le modèle HBS, PBZ a réduit plusieurs indicateurs de douleur comparativement au placebo et au MXM. Le méloxicam n'a pas réduit les indicateurs de douleur par rapport au placebo. Dans le modèle SYN, MXM et PBZ ont réduit les hausses de la température de la peau carpienne comparativement au placebo. Le méloxicam a réduit les scores de boiterie et les changements induits par la boiterie dans le mouvement de la tête comparativement au placebo et à PBZ. La phénylbutazone a réduit le changement du mouvement de la tête induit par la boiterie comparativement au placebo. Dans l'ensemble, PBZ était plus efficace que MXM pour réduire la douleur dans le modèle HBS, tandis que MXM était plus efficace pour réduire la douleur dans le modèle SYN aux doses orales utilisées.(Traduit par Isabelle Vallières).
Asunto(s)
Antiinflamatorios no Esteroideos/administración & dosificación , Cojera Animal/tratamiento farmacológico , Dolor/veterinaria , Fenilbutazona/administración & dosificación , Sinovitis/tratamiento farmacológico , Tiazinas/administración & dosificación , Tiazoles/administración & dosificación , Animales , Femenino , Caballos , Lipopolisacáridos/administración & dosificación , Masculino , Meloxicam , Dolor/tratamiento farmacológico , Temperatura Cutánea/efectos de los fármacos , Sinovitis/veterinaria , Resultado del TratamientoRESUMEN
Phenylbutazone is a non-steroidal anti-inflammatory drug licensed for use in horses to treat musculoskeletal disorders. It is not permitted in the European Union for use in animals destined for the food chain. Official statistics provided by the European Food Safety Authority (EFSA) show that 0.18% of bovines tested in the European Union between 2008 and 2014 for non-steroidal anti-inflammatory drugs were non-compliant, with phenylbutazone representing over 28% of these. Anecdotal evidence suggests animals that have not been treated with the drug may have produced non-compliant samples, possibly through some form of contamination. In this study, ultra-high-performance liquid chromatography coupled with mass-spectrometric detection was applied to bovine plasma samples to determine if detectable residues (CCα = 0.28 ng ml-1) may occur in untreated animals as a result of environmental contamination through normal farming practice. The study demonstrates that waste from animals treated with phenylbutazone, and spread on an area of pasture, can contaminate untreated bovines grazing the pasture many weeks later. It was determined that this contamination, which can persist over a significant period, may be due to the ingestion of as little as 30 µg phenylbutazone by a 500 kg bullock.
Asunto(s)
Antiinflamatorios no Esteroideos/sangre , Residuos de Medicamentos/análisis , Contaminación Ambiental/análisis , Fenilbutazona/sangre , Drogas Veterinarias/sangre , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Bovinos , Cromatografía Líquida de Alta Presión , Control de Medicamentos y Narcóticos/legislación & jurisprudencia , Contaminación de Alimentos/análisis , Herbivoria/fisiología , Caballos , Masculino , Fenilbutazona/administración & dosificación , Ingesta Diaria Recomendada/legislación & jurisprudencia , Espectrometría de Masas en Tándem , Reino Unido , Drogas Veterinarias/administración & dosificaciónRESUMEN
OBJECTIVE: Determine the effects of nonsteroidal anti-inflammatory drugs (NSAID) on platelet function and thromboxane synthesis immediately after drug administration and following 5 days of NSAID administration in healthy horses. STUDY DESIGN: Randomized cross-over study. ANIMALS: Healthy adult horses (n=9; 6 geldings and 3 mares). METHODS: Horses received either flunixin meglumine (1.1 mg/kg IV every 12 hours), phenylbutazone (2.2 mg/kg IV every 12 hours), or firocoxib (loading dose of 0.27 mg/kg IV on day 1, then 0.09 mg/kg IV every 24 hours for 4 days) for a total of 5 days. Blood samples were collected prior to drug administration (day 0), 1 hour after initial NSAID administration (day 1), and then 1 hour post-NSAID administration on day 5. Platelet function was assessed using turbidimetric aggregometry and a platelet function analyzer. Serum thromboxane B2 concentrations were determined by commercial ELISA kit. A minimum 14 day washout period occurred between trials. RESULTS: At 1 hour and 5 days postadministration of firocoxib, flunixin meglumine, or phenylbutazone, there was no significant effect on platelet aggregation or function using turbidimetric aggregometry or a platelet function analyzer. There was, however, a significant decrease in thromboxane synthesis at 1 hour and 5 days postadministration of flunixin meglumine and phenylbutazone that was not seen with firocoxib. CONCLUSION: Preoperative administration of flunixin meglumine, phenylbutazone, or firocoxib should not inhibit platelet function based on our model. The clinical implications of decreased thromboxane B2 synthesis following flunixin meglumine and phenylbutazone administration are undetermined.
Asunto(s)
4-Butirolactona/análogos & derivados , Antiinflamatorios no Esteroideos/administración & dosificación , Plaquetas/efectos de los fármacos , Clonixina/análogos & derivados , Caballos/metabolismo , Fenilbutazona/administración & dosificación , Sulfonas/administración & dosificación , Tromboxanos/metabolismo , 4-Butirolactona/administración & dosificación , 4-Butirolactona/metabolismo , Animales , Antiinflamatorios no Esteroideos/metabolismo , Clonixina/administración & dosificación , Clonixina/metabolismo , Estudios Cruzados , Femenino , Masculino , Fenilbutazona/metabolismo , Sulfonas/metabolismoRESUMEN
Myotonic dystrophy type 1 (DM1) is caused by abnormal expansion of CTG repeats in the 3' untranslated region of the DMPK gene. Expanded CTG repeats are transcribed into RNA and make an aggregate with a splicing regulator, MBNL1, in the nucleus, which is called the nuclear foci. The nuclear foci sequestrates and downregulates availability of MBNL1. Symptomatic treatments are available for DM1, but no rational therapy is available. In this study, we found that a nonsteroidal anti-inflammatory drug (NSAID), phenylbutazone (PBZ), upregulated the expression of MBNL1 in C2C12 myoblasts as well as in the HSA(LR) mouse model for DM1. In the DM1 mice model, PBZ ameliorated aberrant splicing of Clcn1, Nfix, and Rpn2. PBZ increased expression of skeletal muscle chloride channel, decreased abnormal central nuclei of muscle fibers, and improved wheel-running activity in HSA(LR) mice. We found that the effect of PBZ was conferred by two distinct mechanisms. First, PBZ suppressed methylation of an enhancer region in Mbnl1 intron 1, and enhanced transcription of Mbnl1 mRNA. Second, PBZ attenuated binding of MBNL1 to abnormally expanded CUG repeats in cellulo and in vitro. Our studies suggest that PBZ is a potent therapeutic agent for DM1 that upregulates availability of MBNL1.
Asunto(s)
Antiinflamatorios no Esteroideos/administración & dosificación , Proteínas de Unión al ADN/genética , Distrofia Miotónica/tratamiento farmacológico , Fenilbutazona/administración & dosificación , ARN Mensajero/metabolismo , Proteínas de Unión al ARN/genética , Activación Transcripcional/efectos de los fármacos , Animales , Línea Celular , Modelos Animales de Enfermedad , Ratones , Mioblastos/efectos de los fármacos , Mioblastos/metabolismo , Distrofia Miotónica/patología , Empalme del ARN/efectos de los fármacos , ARN Mensajero/genética , Resultado del TratamientoRESUMEN
Methocarbamol (MCBL) is commonly used in performance horses for the treatment of skeletal muscle disorders. Current regulatory recommendations for show horses and racehorses are based on a single oral dose of 5 g, although doses in excess of this are often administered. The goal of the current study was to characterize the disposition of MCBL following higher dose administration and administration in combination with another commonly used drug in performance horses, phenylbutazone (PBZ). Exercised Thoroughbred horses were administered various doses of MCBL as a sole agent and MCBL in combination with PBZ. Blood samples were collected at various times, concentrations of MCBL and PBZ measured using LC-MS/MS and pharmacokinetic parameters calculated using compartmental analysis. Following administration of 15 g of MCBL, either as part of a single- or multiple-dose regimen, a number of horses exceeded the Association of Racing Commissioners International and the United States Equestrian Federation's recommended regulatory threshold at the recommended withdrawal time. There was not a significant difference between horses that received only MCBL and those that received MCBL and PBZ. Results of the current study support an extended withdrawal guideline when doses in excess of 5 g are administered.
Asunto(s)
Antiinflamatorios no Esteroideos/farmacocinética , Metocarbamol/farmacocinética , Relajantes Musculares Centrales/farmacocinética , Fenilbutazona/farmacocinética , Administración Oral , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/sangre , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Quimioterapia Combinada , Femenino , Caballos/sangre , Caballos/metabolismo , Inyecciones Intravenosas , Masculino , Metocarbamol/administración & dosificación , Metocarbamol/sangre , Relajantes Musculares Centrales/administración & dosificación , Relajantes Musculares Centrales/sangre , Pomadas/administración & dosificación , Fenilbutazona/administración & dosificación , Fenilbutazona/sangre , Condicionamiento Físico AnimalRESUMEN
The following study evaluates the overt toxic potential of carprofen (CRP), flunixin (FXN) and phenylbutazone (PBZ) in Old world vultures in relation to historic toxicity data for diclofenac and ketoprofen, with the Cape vulture (Gyps coprotheres) being the indicator species. The toxic potential of a single oral dose of CRP (11.5 mg/kg), FXN (1 mg/kg),PBZ (1.7 mg/kg) or water was evaluated by means of a four-way parallel study (n = 2), as means of ascertaining if these drugs were as toxic as diclofenac in the vulture. No unscheduled deaths or pathological lesions were noted following exposure. Clinical signs of lethargy and depression were, however, noted in one CRP, two FXN and one PBZ treated birds. Mild reversible inhibition of UA excretion was evident in all three groups, although UA remained within the population reference interval in contrast to the effects previously described for diclofenac and ketoprofen. All treatment groups had a drug concentration responsive increase in alanine transferase activity. CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively. While we could not demonstrate a lethal effect of the tested substances, the presence of toxic clinical signs, clinical pathological changes and/or long half-lives of elimination suggests that all three drugs have a potential for toxicity in a larger population or on repeat administration. In conclusion while the studied substances were not as overtly toxic as diclofenac, they are of safety concern.
Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Carbazoles/farmacología , Clonixina/análogos & derivados , Falconiformes , Fenilbutazona/farmacología , Administración Oral , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/efectos adversos , Antiinflamatorios no Esteroideos/farmacocinética , Biomarcadores , Carbazoles/administración & dosificación , Carbazoles/efectos adversos , Carbazoles/farmacocinética , Clonixina/administración & dosificación , Clonixina/efectos adversos , Clonixina/farmacocinética , Clonixina/farmacología , Pruebas de Función Hepática , Fenilbutazona/administración & dosificación , Fenilbutazona/efectos adversos , Fenilbutazona/farmacocinéticaRESUMEN
The presence of anovulatory haemorrhagic follicles during the oestrous cycle of mares causes financial impacts, slowing conception and increasing the number of services per pregnancy. Non-steroidal anti-inflammatory drugs (NSAIDs) such as meloxicam and phenylbutazone are used in the treatment of several disorders in mares, and these drugs can impair the formation of prostaglandins (PGs) and consequently interfere with reproductive activity. This study aimed to evaluate the effects of treatment with NSAIDs on the development of pre-ovulatory follicles in mares. In total, 11 mares were studied over three consecutive oestrous cycles, and gynaecological and ultrasound examinations were performed every 12 h. When 32-mm-diameter follicles were detected, 1 mg of deslorelin was administered to induce ovulation. The first cycle was used as a control, and the mares received only a dose of deslorelin. In the subsequent cycles, in addition to receiving the same dose of deslorelin, each mare was treated with NSAIDs. In the second cycle, 4.4 mg/kg of phenylbutazone was administered, and in the third cycle, 0.6 mg/kg of meloxicam was administered once a day until ovulation or the beginning of follicular haemorrhage. All of the mares ovulated between 36 and 48 h after the induction in the control cycle. In the meloxicam cycle, 10 mares (92%) did not ovulate, while in the phenylbutazone cycle, nine mares (83%) did not ovulate. In both treatments, intrafollicular hyperechoic spots indicative of haemorrhagic follicles were observed on ultrasound. Thus, our results suggested that treatment with meloxicam and phenylbutazone at therapeutic doses induced intrafollicular haemorrhage and luteinization of anovulatory follicles.
Asunto(s)
Antiinflamatorios no Esteroideos/administración & dosificación , Caballos/fisiología , Ovulación/efectos de los fármacos , Fenilbutazona/administración & dosificación , Tiazinas/administración & dosificación , Tiazoles/administración & dosificación , Animales , Ciclo Estral , Femenino , Fase Folicular , Luteinización/efectos de los fármacos , Masculino , Meloxicam , Folículo Ovárico/diagnóstico por imagen , Inducción de la Ovulación/veterinaria , Embarazo , Pamoato de Triptorelina/administración & dosificación , Pamoato de Triptorelina/análogos & derivados , UltrasonografíaRESUMEN
Phenylbutazone (PBZ) is widely used in equine medicine, and its side effects on the gastrointestinal tract are well known. The inhibition of prostaglandins and the oxidative stress induced by nonsteroidal anti-inflammatory drugs (NSAIDs) are described as mechanisms of gastric mucosal injury in humans. In horses, only the secondary effect of changes in cyclooxygenases is related to gastric mucosal injury. The objective of this study was to evaluate the effect of PBZ on certain antioxidative/oxidative parameters of the gastric mucosa. The concentrations of antioxidants and oxidants (superoxide dismutase, SOD; catalase, CAT; nitric oxide, NO; total glutathione, GSH; myeloperoxidase, MPO; and malondialdehyde, MDA), PGE2 levels, and the ulcerative lesions score were assessed. The results demonstrated decreased levels of antioxidant variables, increased levels of oxidant variables, and alterations in the prostaglandin E2 (PGE2 ), myeloperoxidase (MPO), and glutathione (GSH) levels. In conclusion, PBZ induces oxidative stress in the gastric glandular mucosa of horses by changing the antioxidant-oxidant balance of this surface, which might be regarded as another mechanism of injury in the horse stomach.
Asunto(s)
Antiinflamatorios no Esteroideos/efectos adversos , Mucosa Gástrica/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Fenilbutazona/efectos adversos , Administración Oral , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Catalasa/análisis , Dinoprostona/análisis , Femenino , Mucosa Gástrica/química , Mucosa Gástrica/metabolismo , Gastroscopía/veterinaria , Glutatión/análisis , Enfermedades de los Caballos/inducido químicamente , Caballos , Masculino , Malondialdehído/análisis , Óxido Nítrico/análisis , Peroxidasa/análisis , Fenilbutazona/administración & dosificación , Úlcera Gástrica/inducido químicamente , Superóxido Dismutasa/análisisRESUMEN
OBJECTIVE: To compare the effects of 2 NSAIDs (phenylbutazone and meloxicam) on renal function in horses. ANIMALS: 9 Thoroughbred or Standardbred mares (mean ± SD age, 5.22 ± 1.09 years [range, 2 to 12 years]; mean body weight, 470 ± 25 kg [range, 442 to 510 kg]). PROCEDURES: A randomized blinded placebo-controlled crossover study was conducted to examine the effects of treatment with phenylbutazone, meloxicam, or a placebo (control solution) on renal responses to the administration of furosemide, dobutamine, and exercise (15 minutes at 60% of maximum heart rate). Renal function was assessed by use of bilateral ureteral catheterization for simultaneous determination of creatinine clearance, sodium excretion, and urine flow rate. RESULTS: Both phenylbutazone and meloxicam attenuated diuresis and natriuresis and reduced glomerular filtration rate, compared with results for the control solution, when horses were treated with furosemide. Mean arterial blood pressure, urine flow rate, and glomerular filtration rate were increased during or after (or both) dobutamine infusion. Both NSAIDs reduced urine flow rate and sodium excretion associated with dobutamine infusion and exercise but had no effect on glomerular filtration rate. CONCLUSIONS AND CLINICAL RELEVANCE: Responses to meloxicam, a cyclooxygenase (COX)-2 preferential agent, appeared comparable to those detected after phenylbutazone treatment, which suggested that COX-2 was the mediator of prostanoid-induced changes to renal function in horses and indicated that COX-2-preferential agents would be likely to have adverse renal effects similar to those for nonselective COX inhibitors in volume-depleted horses.
Asunto(s)
Dobutamina/farmacología , Furosemida/farmacología , Caballos/fisiología , Riñón/efectos de los fármacos , Fenilbutazona/farmacología , Tiazinas/farmacología , Tiazoles/farmacología , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/farmacología , Cardiotónicos/administración & dosificación , Cardiotónicos/farmacología , Estudios Cruzados , Ciclooxigenasa 2/metabolismo , Diuréticos/farmacología , Dobutamina/administración & dosificación , Femenino , Furosemida/administración & dosificación , Tasa de Filtración Glomerular/efectos de los fármacos , Riñón/fisiología , Masculino , Meloxicam , Fenilbutazona/administración & dosificación , Condicionamiento Físico Animal/fisiología , Sodio/farmacología , Tiazinas/administración & dosificación , Tiazoles/administración & dosificaciónRESUMEN
Simultaneous administration of a nonselective COX inhibitor and a COX-2 specific NSAID has not been previously reported in horses. The goal of this study was to determine the safety of a 10-day dosage regimen of phenylbutazone and firocoxib, both at their standard dosages, in horses. Six horses were administered 2.2 mg/kg of phenylbutazone and 0.1 mg/kg of firocoxib by mouth, daily for 10 days. Horses were assessed daily for changes in behavior, appetite, fecal consistency, signs of abdominal pain, and oral mucous membrane ulceration. Horses were assessed prior to and on the last day of treatment for changes in serum creatinine, albumin, total protein, and urine-specific gravity. Horses underwent endoscopic examination of the esophagus, stomach, and pylorus prior to and 24 hours after the last treatment. A significant change in serum creatinine and total protein was observed on day 10 of treatment. No other significant findings were noted during the experiment. Results indicated that co-administration of phenylbutazone and firocoxib may cause renal disease.
Asunto(s)
4-Butirolactona/análogos & derivados , Antiinflamatorios no Esteroideos/efectos adversos , Enfermedades de los Caballos/inducido químicamente , Enfermedades Renales/veterinaria , Fenilbutazona/efectos adversos , Sulfonas/efectos adversos , 4-Butirolactona/administración & dosificación , 4-Butirolactona/efectos adversos , Administración Oral , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Proteínas Sanguíneas , Creatinina/sangre , Quimioterapia Combinada , Enfermedades de los Caballos/sangre , Caballos , Enfermedades Renales/inducido químicamente , Fenilbutazona/administración & dosificación , Prostaglandina-Endoperóxido Sintasas/metabolismo , Sulfonas/administración & dosificaciónRESUMEN
OBJECTIVE: To assess gene expressions of cyclooxygenase-1 and -2 in oral, glandular gastric, and urinary bladder mucosae and determine the effect of oral administration of phenylbutazone on those gene expressions in horses. ANIMALS: 12 healthy horses. PROCEDURES: Horses were allocated to receive phenylbutazone or placebo (6 horses/group); 1 placebo-treated horse with a cystic calculus was subsequently removed from the study, and those data were not analyzed. In each horse, the stomach and urinary bladder were evaluated for ulceration via endoscopy before and after experimental treatment. Oral, glandular gastric, and urinary bladder mucosa biopsy specimens were collected by use of a skin punch biopsy instrument (oral) or transendoscopically (stomach and bladder) before and after administration of phenylbutazone (4.4 mg/kg, p.o., q 12 h) in corn syrup or placebo (corn syrup alone) for 7 days. Cyclooxygenase-1 and -2 gene expressions were determined (via quantitative PCR techniques) in specimens collected before and after the 7-day treatment period and compared within and between groups. Prior to commencement of treatment, biopsy specimens from 7 horses were used to compare gene expressions among tissues. RESULTS: The cyclooxygenase-1 gene was expressed in all tissues collected. The cyclooxygenase-2 gene was expressed in the glandular gastric and bladder mucosae but not in the oral mucosa. Cyclooxygenase gene expressions were unaffected by phenylbutazone administration. CONCLUSIONS AND CLINICAL RELEVANCE: Cyclooxygenase-2 was constitutively expressed in glandular gastric and bladder mucosae but not in the oral mucosa of healthy horses. Oral administration of phenylbutazone at the maximum recommended dosage daily for 7 days did not affect cyclooxygenase-1 or -2 gene expression.
Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Ciclooxigenasa 1/genética , Ciclooxigenasa 2/genética , Regulación de la Expresión Génica/efectos de los fármacos , Caballos/metabolismo , Membrana Mucosa/efectos de los fármacos , Fenilbutazona/farmacología , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Cistoscopía/veterinaria , Femenino , Gastroscopía/veterinaria , Masculino , Boca/efectos de los fármacos , Boca/patología , Membrana Mucosa/patología , Fenilbutazona/administración & dosificación , Reacción en Cadena de la Polimerasa/veterinaria , ARN Mensajero/metabolismo , Estómago/efectos de los fármacos , Estómago/patología , Vejiga Urinaria/efectos de los fármacos , Vejiga Urinaria/patologíaRESUMEN
REASON FOR PERFORMING STUDY: Using an adjustable heart bar shoe model of foot pain, the objective of this study was to test the hypothesis that the combined use of phenylbutazone (PBZ) and flunixin meglumine (FM) would prove more efficacious in alleviating lameness than either drug alone. MATERIALS AND METHODS: One hour after induction of lameness at weekly intervals, 8 healthy adult Thoroughbred horses randomly underwent one of 4 i.v. treatments: saline (SAL) placebo (1 ml/45 kg bwt), PBZ (4.4 mg/kg bwt), FM (1.1 mg/kg bwt) or PBZ+FM (at the same dosages as given individually). Heart rate (HR) and lameness score (LS) responses were assessed in a blinded manner every 20 min for 5 h after lameness induction and then hourly for 12 h after treatment. Jugular venous blood samples were obtained at -1, 0, 0.05, 1, 2, 4, 6, 8, 10 and 12 h and subsequently analysed for drug concentrations. Repeated measures ANOVA and post hoc Tukey's test were used to identify analgesic effects at a significance level of P<0.05. RESULTS: Heart rate was lower in all nonsteroidal anti-inflammatory drug (NSAID)-treated trials from 2 h to 10 h post treatment (P<0.05). Analgesic effects of FM and PBZ+FM, as evidenced by decreases in HR, lasted for 12 h post treatment (P<0.05). Lameness score decreased earlier in PBZ and PBZ+FM trials than in FM trials (P<0.05) and the analgesic effect on LS lasted for 12 h post treatment for all NSAID trials (P<0.05). Peak PBZ plasma concentration was 73.7 ± 6.0 and 77.9 ± 5.5 µg/ml. Peak FM concentration was 12.0 ± 0.8 and 13.7 ± 1.0 µg/ml. CONCLUSIONS: It was concluded that the combination of PBZ+FM was not more effective than either PBZ or FM alone. These data do not support the hypothesis that the combination is more efficacious at these dosages than either drug alone in this model of acute foot pain.
Asunto(s)
Clonixina/análogos & derivados , Enfermedades de los Caballos/tratamiento farmacológico , Cojera Animal/tratamiento farmacológico , Dolor/veterinaria , Fenilbutazona/uso terapéutico , Animales , Clonixina/administración & dosificación , Clonixina/sangre , Clonixina/farmacocinética , Clonixina/uso terapéutico , Estudios Cruzados , Quimioterapia Combinada , Femenino , Enfermedades del Pie/tratamiento farmacológico , Enfermedades del Pie/veterinaria , Frecuencia Cardíaca , Caballos , Masculino , Dolor/tratamiento farmacológico , Fenilbutazona/administración & dosificación , Fenilbutazona/sangre , Fenilbutazona/farmacocinética , Factores de TiempoRESUMEN
CASE DESCRIPTION: A 15-year-old Quarter Horse gelding and a 26-year-old Thoroughbred gelding were evaluated because of hematuria of 4 to 6 days' duration following prolonged oral administration of phenylbutazone. CLINICAL FINDINGS: The horses had received either treatment with phenylbutazone for 3 months or intermittent long-term phenylbutazone treatment prior to development of hematuria. Each horse was systemically stable but had orthopedic or neurologic problems. Clinicopathologic findings included normochromic normocytic anemia in both horses and hypoalbuminemia and high BUN concentration in 1 horse. In both horses, urinalysis revealed proteinuria and RBCs, but no evidence of WBCs or bacteria. Ulceration and hemorrhage of the urinary bladder with no evidence of uroliths were observed via cystoscopy. Gastric ulceration along the margo plicatus was observed via gastroscopy. TREATMENT AND OUTCOME: For each horse, phenylbutazone treatment was discontinued and a synthetic prostaglandin (misoprostol) was administered. The hematuria resolved, and results of a follow-up CBC, serum biochemical analysis, urinalysis, and cystoscopy 25 or 30 days after cessation of phenylbutazone treatment were unremarkable in both cases. CLINICAL RELEVANCE: Given the known adverse effects of NSAID treatment in several species, phenylbutazone and its metabolites were suspected to have caused ulceration of the urinary bladder, resulting in hematuria, in the 2 horses. A definitive cause of urinary bladder ulceration was not confirmed in these cases; however, resolution of ulceration after discontinuation of phenylbutazone treatment and administration of synthetic prostaglandins and exclusion of other causes suggested an association between phenylbutazone administration and ulcerative cystitis in these horses.
Asunto(s)
Antiinflamatorios no Esteroideos/efectos adversos , Cistitis/veterinaria , Hematuria/veterinaria , Enfermedades de los Caballos/inducido químicamente , Fenilbutazona/efectos adversos , Animales , Antiulcerosos/uso terapéutico , Cistitis/inducido químicamente , Hematuria/inducido químicamente , Caballos , Masculino , Misoprostol/uso terapéutico , Omeprazol/uso terapéutico , Fenilbutazona/administración & dosificación , Fenilbutazona/uso terapéutico , Úlcera/inducido químicamente , Úlcera/tratamiento farmacológico , Úlcera/veterinariaRESUMEN
OBJECTIVE: To characterize the cardiorespiratory and electrocardiographic effects of the combined administration of phenylbutazone and romifidine. STUDY DESIGN: Prospective four-period, four-treatment, blinded, randomized, crossover trial. ANIMALS: Five, healthy, mixed breed horses. METHODS: Prior to treatment administration, a catheter was introduced into the intra-thoracic cranial vena cava via the jugular vein and a subcutaneously located carotid artery was catheterised. All treatments were administered intravenously (IV) and consisted of saline placebo (PLC), phenylbutazone (PBZ, 4.4 mg kg(-1) ) romifidine (ROM, 80 µg kg(-1) ) and a combination of phenylbutazone (4.4 mg kg(-1) ) and romifidine (80 µg kg(-1) ). There was at least a 1 week washout period between treatments. Heart rate (HR), respiratory rate (f(R) ), systolic (SAP), diastolic (DAP) and mean (MAP) arterial pressures and central venous pressure (CVP) were recorded for baseline (prior to drug administration) and at 5 minute intervals thereafter for 30 minutes. Electrocardiographic abnormalities were recorded. Data were analyzed by anova. RESULTS: For the cardiovascular variables there were no statistically significant (p>0.05) differences between horses treated with ROM and PBZ_ROM. Statistically significant (p<0.05) differences only occurred between treatments with romifidine (ROM and PBZ_ROM) and without romifidine (PLC and PBZ). Within treatments, for ROM, changes over time were statistically significant (p<0.05) for HR, SAP, DAP, MAP and CVP. For PBZ_ROM, changes over time were statistically significant (p<0.05) for CVP. Sino-atrial and atrio-ventricular blocks occurred in horses treated with ROM and PBZ_ROM. CONCLUSIONS AND CLINICAL RELEVANCE: The combined IV administration of phenylbutazone and romifidine had no statistically significant effect on cardiorespiratory variables. These limited data suggest no evidence why both agents should not be included in a preoperative medication protocol for healthy horses but do not exclude the possibility of interactions occurring in a larger population.
Asunto(s)
Anestesia Intravenosa/veterinaria , Anestésicos Combinados/administración & dosificación , Anestésicos Intravenosos/administración & dosificación , Imidazoles/administración & dosificación , Fenilbutazona/administración & dosificación , Anestesia Intravenosa/métodos , Anestésicos Combinados/farmacología , Anestésicos Intravenosos/farmacología , Animales , Presión Sanguínea/efectos de los fármacos , Frecuencia Cardíaca/efectos de los fármacos , Caballos , Imidazoles/farmacología , Fenilbutazona/farmacología , Frecuencia Respiratoria/efectos de los fármacosRESUMEN
Verificaram-se os efeitos da associação de furosemida e fenilbutazona sobre variáveis hidroeletrolíticas de cavalos antes e após a corrida. Dezenove equinos foram distribuídos em três grupos, de acordo com os protocolos de tratamento. O primeiro grupo, de cinco animais, não recebeu medicação (grupo-controle); o segundo grupo, de sete animais, foi tratado com furosemida, na dose de 1mg/kg, por via intramuscular, até quatro horas antes do páreo; o terceiro, de sete animais, recebeu furosemida, por via intramuscular, e fenilbutazona, por via intravenosa, nas doses de 1,0 e 4,4mg/kg, respectivamente, até quatro horas antes da corrida. Amostras de sangue foram colhidas antes, imediatamente após e duas horas após o páreo, para avaliação da osmolalidade plasmática e das concentrações plasmáticas de sódio, potássio e cloreto. A utilização de furosemida e da associação furosemida e fenilbutazona até 4h antes dos páreos nas dosagens descritas alterou (P<0,05) a osmolalidade plasmática dos equinos, mas não alterou (P>0,05) as concentrações de sódio, potássio e cloreto. Os páreos alteraram de forma fisiológica a osmolalidade plasmática e a concentração sanguínea de K+ devido ao exercício de alta intensidade.
The objective of this study was to verify the effects of furosemide and phenylbutazone association on fluid and electrolyte balance characteristics of horses before and after a race. Nineteen horses were divided into three groups according to treatment protocols. The first group (five animals - control) was not medicated. A second group (seven animals) was treated with furosemide (1mg/kg, intramuscular up to four hours before the race). A third group (seven animals) received furosemide (1mg/kg) and phenylbutazone (4.4mg/kg), both intramuscular, up to four hours before race. Blood samples were collected before, immediately after and two hours after a race to evaluate the plasma osmolality and sodium, potassium and chloride concentrations. The use of furosemide and furosemide plus phenylbutazone up to four hours before the race altered (P<0.05) the plasma osmolality but did not change (P>0.05) the sodium, potassium and chloride concentrations. It was not possible to determine an antagonist effect of phenylbutazone on furosemide, based on fluid and electrolyte balance. Due to the high intensity exercise, the increase in plasma osmolality and potassium concentration was attributed to the race effect.
Asunto(s)
Animales , Electrólitos/metabolismo , Fenilbutazona/administración & dosificación , Furosemida/administración & dosificación , Concentración Osmolar , Caballos/metabolismo , Potasio , SodioRESUMEN
PURPOSE: The purpose of this study was to evaluate the brain, renal, and hepatic effects of three NSAIDs (flunixin meglumine, ketoprofen, and phenylbutazone) when administered IV to clinically normal Iranian fat-tailed sheep. METHODS: The experiments were conducted on twenty clinically normal adult female sheep. Sheep were randomly assigned to four groups: saline (n = 5), flunixin meglumine (n = 5), ketoprofen (n = 5), and phenylbutazone (n = 5). Drug administration was initiated at 8 AM: on day 1 and continued every 12 h for 12 days. Flunixin meglumine, ketoprofen, and phenylbutazone were administered at dose rate of 2.2, 4, and 4 mg/kg, respectively. Daily blood and urine samples were collected from all sheep for hematologic, enzymes activity, and urinalysis. Immediately after euthanasia, complete necropsy was performed on all sheep and gross lesions were recorded. RESULTS: Clinical, hematological, serum, and urine analysis and histopatholgical findings were described. CONCLUSION: When the use of these compounds is contemplated in clinical cases, the risk of adverse effects and the comparative toxic potential should be considered, along with the efficacy of the compound for the condition being treated.